Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

Completed · Phase 1/Phase 2

Conditions studied: Myelodysplastic Syndrome (MDS)

In brief

The purpose of this study is to determine the safety and efficacy of TLK199 Tablets in patients with Myelodysplastic Syndrome (MDS)

Key facts

Study ID

NCT00280631

Run by

Telik

People needed

49

Starts

2006-02-01

Expected to finish

2008-06-01

Last updated by the study team

2012-05-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diagnosis of MDS
• Documented significant cytopenia for at least 2 months
• Adequate liver and kidney function
• Ineligible for stem cell bone marrow transplantation
• At least 18 years of age
• Discontinuation of growth factors (e.g., G-CSF) within 3 weeks of study entry

You may not qualify if…

• Prior bone marrow transplant
• Failure to recover from any prior surgery or any major surgery within 4 weeks of study entry
• Pregnant or lactating women
• Other investigational drugs within 14 days of study entry
• Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry

Where it is running

• Loyola University Chicago-Cardinal Bernardin Cancer Center — Maywood, Illinois, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• University of Massachusetts (UMass) Memorial Medical Center — Worcester, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.